🇺🇸 FDA
Patent

US 10626399

Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)

granted A61KA61K2039/505A61K31/00

Quick answer

US patent 10626399 (Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)) held by United States Government as represented by the Department of Veterans Affairs expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Government as represented by the Department of Veterans Affairs
Grant date
Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K2039/505, A61K31/00, A61K31/7088, A61K38/19